JP2021519272A5 - - Google Patents

Info

Publication number
JP2021519272A5
JP2021519272A5 JP2020551353A JP2020551353A JP2021519272A5 JP 2021519272 A5 JP2021519272 A5 JP 2021519272A5 JP 2020551353 A JP2020551353 A JP 2020551353A JP 2020551353 A JP2020551353 A JP 2020551353A JP 2021519272 A5 JP2021519272 A5 JP 2021519272A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
dose
dopamine
levodopa
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020551353A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021519272A (ja
JP7485874B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SE2019/050260 external-priority patent/WO2019182506A1/en
Publication of JP2021519272A publication Critical patent/JP2021519272A/ja
Publication of JP2021519272A5 publication Critical patent/JP2021519272A5/ja
Application granted granted Critical
Publication of JP7485874B2 publication Critical patent/JP7485874B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020551353A 2018-03-23 2019-03-22 神経変性障害の治療のための医薬組成物の連続的投与 Active JP7485874B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1850327-6 2018-03-23
SE1850327 2018-03-23
PCT/SE2019/050260 WO2019182506A1 (en) 2018-03-23 2019-03-22 Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders

Publications (3)

Publication Number Publication Date
JP2021519272A JP2021519272A (ja) 2021-08-10
JP2021519272A5 true JP2021519272A5 (https=) 2023-09-07
JP7485874B2 JP7485874B2 (ja) 2024-05-17

Family

ID=66041617

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020551353A Active JP7485874B2 (ja) 2018-03-23 2019-03-22 神経変性障害の治療のための医薬組成物の連続的投与

Country Status (16)

Country Link
US (3) US11547689B2 (https=)
EP (1) EP3768263B1 (https=)
JP (1) JP7485874B2 (https=)
KR (2) KR20200136008A (https=)
CN (2) CN118121710A (https=)
AU (1) AU2019237857B2 (https=)
ES (1) ES3053690T3 (https=)
HR (1) HRP20251502T1 (https=)
IL (1) IL277553B2 (https=)
MY (1) MY199846A (https=)
NZ (1) NZ768098A (https=)
PH (1) PH12020551527A1 (https=)
PL (1) PL3768263T3 (https=)
RS (1) RS67469B1 (https=)
SG (1) SG11202009215PA (https=)
WO (1) WO2019182506A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113197851A (zh) 2015-05-06 2021-08-03 辛纳吉勒公司 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法
EP3768263B1 (en) 2018-03-23 2025-10-29 LobSor Pharmaceuticals Aktiebolag Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004348D0 (en) 1990-02-27 1990-04-25 Orion Yhtymae Oy New use of catechol derivatives and their physiologically acceptable salts and esters
SE9203594D0 (sv) 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
US20080118556A1 (en) * 1998-11-02 2008-05-22 Elan Corporation, Plc Modified Release of Compositions Containing a Combination of Carbidopa, Levodopa and Entacapone
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
DE602004031134D1 (de) 2003-08-29 2011-03-03 Transform Pharmaceuticals Inc Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
EP1796687A2 (en) * 2004-09-14 2007-06-20 Elixir Pharmaceuticals, Inc. Combination therapy for controlled carbohydrate digestion
CN101132777A (zh) * 2004-12-20 2008-02-27 科利吉姆制药公司 用于睡眠障碍的药物组合物
US20060222703A1 (en) 2005-04-01 2006-10-05 Iprbox Oy Pharmaceutical composition and preparation method thereof
WO2007138086A1 (en) 2006-05-31 2007-12-06 Solvay Pharmaceuticals Gmbh Long term 24 hour intestinal administration of levodopa/carbidopa
US8741342B2 (en) * 2006-10-30 2014-06-03 Wockhardt Research Centre Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa
EP2252284B1 (en) 2008-02-06 2011-05-25 Wockhardt Research Centre Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability
CN102202656A (zh) * 2008-08-15 2011-09-28 蒂宝制药公司 治疗和预防cns障碍的胃滞留药用组合物
EA026419B1 (ru) 2010-03-04 2017-04-28 Орион Корпорейшн Применение леводопы, карбидопы и энтакапона для лечения болезни паркинсона
PT2640358T (pt) 2010-11-15 2018-02-23 Neuroderm Ltd Administração contínua de l-dopa, inibidores de dopa descarboxilase, inibidores de catecol-o-metil transferase e composições para os mesmos
WO2012147099A1 (en) 2011-04-25 2012-11-01 Suven Nishtaa Pharma Pvt. Ltd. Pharmaceutical compositions of levodopa, carbidopa and entacapone
JP6622310B2 (ja) * 2014-09-04 2019-12-18 ロブソル・ファーマシューティカルズ・アクチボラグＬｏｂｓｏｒ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ａｋｔｉｅｂｏｌａｇ レボドパ、ドーパミン脱炭酸酵素阻害薬およびｃｏｍｔ阻害薬を含む医薬組成物ならびにその投与方法
US10555922B2 (en) * 2015-09-04 2020-02-11 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
EP3768263B1 (en) * 2018-03-23 2025-10-29 LobSor Pharmaceuticals Aktiebolag Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders

Similar Documents

Publication Publication Date Title
US12156858B2 (en) Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof
US10555922B2 (en) Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
US20250213518A1 (en) Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders
JP2021519272A5 (https=)
HK40110793A (en) Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comtinhibitor and method of administration thereof
HK40044749A (en) Pharmaceutical gel compositions comprising levodopa, carbidopa and entacapone
HK40044749B (en) Pharmaceutical gel compositions comprising levodopa, carbidopa and entacapone